Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 10(63), 2019

DOI: 10.1128/aac.00263-19

Links

Tools

Export citation

Search in Google Scholar

Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study

Journal article published in 2019 by Hanane Yousfi, Carole Cassagne, Stéphane Ranque ORCID, Jean-Marc Rolain, Fadi Bittar ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The use of antifungal agents in clinical settings is limited by the appearance of drug resistance and adverse side effects. There is, therefore, an urgent need to develop new drugs to strengthen the treatment of invasive fungal diseases. The aim of this study is to describe the potential repurposing of ribavirin as an adjunct therapy against Candida spp. Primary screening of a Prestwick Chemical library against Candida albicans ATCC 90028 and fluconazole-resistant Candida albicans strains was performed.